Entity stock epinephrine laws are state statutes that let a qualifying business, venue, or organization keep epinephrine auto-injectors on the premises for use on anyone suffering anaphylaxis, without a patient-specific prescription. Roughly 35 states have enacted them. Participation is voluntary, but once you opt in, the law spells out how to obtain the medication, who can administer it, how it must be stored, and what liability protection applies. If your operation puts staff around food allergens, insect stings, or large crowds, the framework is worth understanding, because anaphylaxis moves fast and the person reacting often didn’t know they were allergic.
Which Businesses Can Participate
State laws typically define an “authorized entity” as an organization where allergens are commonly present or where professional medical help could be delayed. The categories that usually qualify:
- Food-service businesses, including restaurants, catering companies, grocery stores, and food courts.
- Recreation and entertainment venues such as theme parks, sports stadiums, concert halls, and movie theaters.
- Youth-serving organizations, including daycare centers, summer camps, and after-school programs.
- Outdoor and public spaces such as parks, pools, and recreational facilities, where insect stings are a common trigger.
- In a smaller number of states, colleges, universities, and large employers.
Being in one of these categories does not by itself make you an authorized entity. You become one by building the program: securing a standing order, training designated staff, setting up compliant storage, and adopting a written emergency action plan.
Getting a Standing Order
The legal mechanism that makes the whole program work is the standing order, sometimes called a non-patient-specific prescription. A licensed healthcare provider, typically a physician and in some states a nurse practitioner or physician assistant, issues a written authorization that lets a pharmacy or manufacturer sell auto-injectors to your organization rather than to a named patient. Without that order, holding undesignated epinephrine would violate prescription drug law.
The provider issuing the order takes on professional responsibility. They will generally want to see that you have a written emergency action plan, that designated staff will be trained, and that storage and reporting are handled. Some states require the standing order to be renewed annually; others leave the interval to the prescriber. Confirm your renewal timeline with both the provider and your state health department.
Finding a willing prescriber is often the slowest step. Some state health departments maintain lists of participating physicians, and allergy organizations occasionally connect entities with prescribers. Rural operators and businesses without an existing allergist relationship should plan on a longer lead time.
Training Designated Staff
Every entity law requires that at least some employees complete a certified training program before the organization can stock epinephrine. Training is what legally allows a non-clinician to administer a prescription drug. The American Red Cross offers dedicated anaphylaxis and auto-injector courses, and many states accept programs approved by the state health department or board of pharmacy.
A typical course covers recognizing anaphylaxis, the difference between adult and pediatric dosing, the mechanics of operating an auto-injector, and what to do immediately after administration. The emphasis throughout is speed. Epinephrine works best when given early, and hesitation costs lives.
Most states require at least one trained employee to be on-site during all operating hours. Keep training records and certifications at the business location and available for inspection. Letting certifications lapse is not just a paperwork issue; it can void the legal protections the program depends on.
Storage, Inspection, and Expiration
Epinephrine degrades when exposed to temperature extremes or light. FDA-approved labeling specifies storage at 68°F to 77°F, with temporary excursions permitted between 59°F and 86°F. Keep devices in their protective carrier tubes. Do not refrigerate or freeze them, despite the intuition that cold storage preserves medication. A glove box, a spot near a kitchen stove, or a shelf in direct sunlight can render an auto-injector useless.
Monthly inspections are standard practice. During each check, a designated employee should confirm that storage temperature is within range, that the solution visible through the viewing window is clear and free of particles, that packaging is intact, and that the device has not expired. Log the inspection with a date and signature.
Auto-injectors typically carry a labeled shelf life of about 12 to 20 months from manufacture, and by the time a device reaches you it may have less remaining. Replacement is a recurring cost, not a one-time purchase. Stocking or using expired devices undermines the program’s legal standing and may fail the person who needs it.
What to Do During a Manufacturer Recall
Auto-injectors have been subject to manufacturer recalls, most notably for device activation failures. When the FDA publishes affected lot numbers, act quickly, but do not discard the recalled devices until replacements arrive. A recalled device with a potential defect is still better than no device during an anaphylactic emergency. Once replacements are in hand, return the recalled units following the manufacturer’s instructions.
Recognizing Anaphylaxis and Administering the Injection
Trained staff should administer stock epinephrine when they see signs of a severe allergic reaction. Watch for shortness of breath, repetitive coughing, throat tightness or swelling, widespread hives or flushing, a weak or rapid pulse, vomiting or diarrhea combined with skin symptoms, and dizziness or loss of consciousness. Anaphylaxis usually involves more than one body system at once, and that pattern is what distinguishes it from a milder reaction.
When in doubt, give the injection. The risk of administering unnecessarily is far smaller than the risk of withholding during genuine anaphylaxis. Epinephrine is the only first-line treatment; antihistamines will not reverse airway swelling or dangerously low blood pressure.
Most auto-injectors are designed for injection into the outer thigh and can be used through clothing. The authority to administer applies to anyone on the premises experiencing a severe reaction, whether or not they have a known allergy or a personal prescription.
Calling 911 and Filing an Incident Report
Epinephrine is a bridge, not a cure. Its effects are temporary, and symptoms can rebound. Call 911 immediately on recognizing anaphylaxis, ideally before or at the same time as the injection. Virtually every state entity law requires it. The person who received the injection must be evaluated by emergency medical personnel even if they seem to recover quickly.
Most states also require the entity to complete an incident report after any use. Requirements vary. Some states demand notification to the prescribing physician and a state agency within a defined timeframe; others leave the details to internal policy. At a minimum, document the time symptoms were first observed, the time of injection, the symptoms that prompted administration, the dose given, and the patient’s response. That record serves the arriving EMS team and any future regulatory review.
What the Program Costs
Medication is the biggest recurring expense. Brand-name EpiPen two-packs run roughly $350 to $700 at retail. The authorized generic of the same device is available for about $175 to $300 per two-pack, and other generics fall in a similar range. Most programs stock at least two auto-injectors, and entities serving both adults and children should keep adult-dose (0.3 mg) and pediatric-dose (0.15 mg) units. Initial purchase can range from about $350 to over $1,000 depending on the product and unit count.
Beyond the devices, budget for training each designated employee, the physician’s fee for issuing and renewing the standing order, a sharps disposal container and pickup service, and the administrative time for monthly inspections and recordkeeping. Because auto-injectors expire, this is an annual line item. Manufacturer savings programs exist for commercially insured buyers but may not apply to entities purchasing under a standing order rather than a patient prescription. Check with the manufacturer directly.
Liability Protection and Where It Ends
Fear of being sued for administering medication to a stranger is the biggest barrier to adoption, and legislatures wrote the laws with that in mind. Virtually every entity epinephrine statute includes a liability shield covering the entity, the employee who administers the injection, and the provider who issued the standing order. When everyone followed the law’s requirements, including a valid standing order, current training, proper storage, and good-faith administration, civil liability for adverse outcomes is generally barred.
This statutory immunity is distinct from general Good Samaritan protection, and the distinction matters. Many state Good Samaritan laws do not cover people acting within the scope of paid employment. An employee trained to administer epinephrine as part of their job may not qualify as a Good Samaritan under the traditional definition, so the entity-specific statute is what fills the gap. That is a strong reason to operate under a formal program rather than relying on general Good Samaritan coverage.
When Immunity Fails
Protection is not unconditional. Gross negligence, meaning a reckless disregard for safety so extreme it looks almost intentional, will void immunity in every state that has addressed the question. Stocking devices you know are expired and doing nothing to replace them, failing to call 911 after administration, injecting someone without any training, or ignoring clearly visible signs of medication degradation can all cross that line. Ordinary mistakes made in a high-stress emergency are exactly what the immunity is designed to forgive. Systemic failures in maintaining the program are not.
Review your state’s specific immunity language with counsel. Scope varies. Some states broadly immunize all authorized entities; others define the term more narrowly. A few remain silent on certain aspects of liability, which creates ambiguity a plaintiff’s attorney could work with.
Disposing of Used and Expired Auto-Injectors
Epinephrine auto-injectors contain a needle and are classified as medical sharps whether or not they have been used. The FDA recommends placing a used device immediately into a puncture-resistant sharps disposal container, never into regular trash. When the container is about three-quarters full, dispose of it according to your local guidelines.1U.S. Food and Drug Administration. Best Way to Get Rid of Used Needles and Other Sharps
There is no single federal disposal rule. Options vary by location and may include drop-off sites at pharmacies, hospitals, or fire stations; mail-back programs using FDA-cleared containers; household hazardous waste collection sites; or special waste pickup services. Contact your local health department or call the Safe Needle Disposal hotline at 1-800-643-1643 to find out what is available in your area. Expired but unused auto-injectors follow the same rules. They still contain a needle and cannot go in regular trash.
State Law Is Where the Details Live
Because these are state laws rather than a single federal program, the specifics depend on where you operate. The variables include which entities qualify, how many auto-injectors must be stocked, which training programs are accepted, how often standing orders must be renewed, and the exact scope of liability protection. Your state health department or board of pharmacy is the best starting point, and some states publish stock epinephrine program pages with standing order templates, approved training providers, and reporting forms.
If you operate in more than one state, each location needs its own standing order and compliance program tuned to that state’s law. A program that satisfies Illinois requirements may fall short in Georgia. The core framework is similar everywhere, but the specifics diverge enough that treating compliance as a state-by-state project is the safest approach.